Across TCGA pan-cancer cohorts, LINC01832 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated LINC01832 data layer.
The strongest signal is observed in mesothelioma (MESO), where higher LINC01832 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated LINC01832 expression acts as an unfavorable survival marker, although some lineages such as KIRC and SARC show a favorable association.
MESO, UCEC, and STAD are the cancer types where LINC01832 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.